title: Rapid succession of peripheral blood progenitor cell mobilization cycles in patients with chronic heart failure: effects on the hematopoietic system.
abstract: BACKGROUND
  Circulating hematopoietic peripheral blood progenitor cells (PBPCs) may contribute to the regeneration of nonhematopoietic organs. An increase in circulating PBPC numbers may enhance this process. Therefore, an exploratory trial of repeated PBPC mobilization in patients with chronic heart failure was conducted. The safety and cardiovascular efficacy data have been described elsewhere. In the hematopoietic system, the trial offered an opportunity to study several new aspects of granulocyte-colony-stimulating factor (G-CSF) action.
  
  
  METHODS
  Fourteen male patients with chronic heart failure were treated successively with G-CSF (four 10-day treatment periods interrupted by treatment-free intervals of equal length; daily dose adjustment to maintain a white blood cell [WBC] count of 45 x 10(9)-50 x 10(9)/L).
  
  
  RESULTS
  G-CSF induced a rapid increase in cells of all WBC lineages with return to levels equal to (neutrophilic, eosinophilic, and basophilic granulocytes) or lower than those before treatment (monocytes, lymphocytes) during the treatment-free intervals. Red cell counts remained unchanged, but platelet counts decreased followed by rebound thrombocytosis. The extent of CD34+ cell mobilization was highly variable. For each patient, the changes induced were identical through all cycles, but the G-CSF dose required in the first cycle was significantly higher than in subsequent cycles. In the cohort of patients, an inverse correlation was observed between the WBC level reached and the dose of G-CSF administered.
  
  
  CONCLUSIONS
  Rapid alternation between PBPC mobilization and recovery periods is feasible, with identical alterations in all treatment cycles. G-CSF responsiveness varies among patients and is increased by pretreatment with G-CSF.
authors.affiliation: Hematology Clinic and the Cardiology Clinic, Center for Internal Medicine, University Hospital, Essen, Germany. andreas.huettmann@uniessen.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Hüttmann
authors.forename: Achim
authors.initials: A
authors.lastname: Gutersohn
authors.forename: Richard
authors.initials: R
authors.lastname: Noppeney
authors.forename: Till
authors.initials: T
authors.lastname: Neumann
authors.forename: Raimund
authors.initials: R
authors.lastname: Erbel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Dührsen
mesh_terms: D000368:Aged; D018952:Antigens, CD34; D002908:Chronic Disease; D015331:Cohort Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006333:Heart Failure / Q000097:blood / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor